Dear Editor,

Recurrent Guillain-Barré syndrome (GBS) is a rare condition that reportedly appears in 2--5% of patients with GBS.[@B1] The clinical and pathophysiological characteristics of recurrent GBS have not been fully elucidated. Anti-ganglioside antibodies have been reported in a small number of cases of recurrent GBS. Herein we report on a case of recurrent GBS with anti-GT1a and anti-GQ1b ganglioside antibodies.

A previously healthy 63-year-old man arrived at the emergency room with a 1-day history of dysarthria and right facial sensory change. Additional symptoms of facial diplegia, external ophthalmoplegia, truncal ataxia, and areflexia developed on the third day of admission. The findings of a nerve conduction study (NCS) and CSF analysis were unremarkable. Anti-ganglioside study was performed using the enzyme-linked immunosorbent assay for anti-ganglioside antibodies as described previously,[@B2] and revealed positivity for anti-GT1a (3+) and anti-GQ1b (1+) IgG antibodies. Intravenous immunoglobulin (IVIG) was administered at 0.4 g/kg/day for 5 days from the sixth day after onset. The symptoms of the patient improved gradually after IVIG termination. At 10 days after the 5-day course of IVIG, his neurological deficits had fully recovered except for the ophthalmoplegia. The remaining ophthalmoplegia improved following bilateral medial rectus muscle resection at 6 months after symptom onset. The patient could perform all of the normal activities of daily living, including driving, after the procedure.

The patient was readmitted 12 months after the first attack complaining of paresthesia in both legs. An upper respiratory infection had appeared 1 week previously. These symptoms progressed from both lower extremities to both upper extremities and his face. A neurological examination revealed truncal ataxia and hyporeflexia in both upper and lower extremities along with paresthesia. A CSF analysis produced unremarkable findings, while a motor NCS revealed prolonged distal motor latency with conduction blocks in the bilateral median and ulnar nerves. A sensory NCS revealed the absence of distal sensory nerve action potentials in the median, ulnar, peroneal, and sural nerves. The anti-ganglioside antibody assay was positive for anti-GT1a (1--2+) and anti-GQ1b (1--2+) IgG antibodies, which were the same antibodies present during the previous attack. A laboratory test indicated that the vitamin levels and thyroid function were within the normal limits. Brain MRI findings were unremarkable. Following a diagnosis of GBS, IVIG was administered at 0.4 g/kg/day for 5 days from the day after symptom onset, but his symptoms worsened. Ophthalmoplegia and quadriplegia developed on the fifth day from symptom onset. His symptoms appeared to gradually improve after IVIG termination, but they worsened again 2 weeks later. A second cycle of IVIG at 0.4 g/kg/day for 5 days was administered from day 20 after symptom onset. The patient had recovered fully at 1 month after the second cycle of IVIG treatment.

This patient had experienced two independent episodes of GBS involving the presence of the same anti-ganglioside antibodies during each attack. A few cases of recurrent GBS with anti-ganglioside antibodies have been reported, and are summarized in [Table 1](#T1){ref-type="table"}.[@B3][@B4][@B5] Previous reports of recurrent GBS with anti-ganglioside antibodies have described shorter intervals between the attacks and more-severe neurological deterioration during recurrences. Recurrent GBS is typically reported to present with similar clinical manifestations during different attacks even when different conditions are present prior to the attacks.[@B3] However, some cases of recurrent GBS with different phenotypes during recurrent attacks have been reported.[@B4] These findings suggest that genetic or immunological factors are associated with the pathogenesis of recurrent GBS.

In conclusion, the clinical manifestations of recurrent GBS are heterogeneous, and the associated risk factors remain unclear. Genetic and immunological host factors and anti-ganglioside antibodies might affect the clinical manifestations and pathophysiology of recurrent GBS. Further studies are needed to obtain a deeper understanding of the clinical and pathophysiological factors underlying recurrent GBS.
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###### Anti-ganglioside antibodies in recurrent Guillain-Barré syndrome
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  No.   Sex      Age, years        Episode                                                                                Preceding infection                        Clinical manifestations                                       NCS findings                               Ganglioside Abs Reference     
  ----- -------- ----------------- -------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------- ------------------------------------------ ----------------------------- ----------
  1     F        38                First                                                                                  Gastroenteritis                            Quadriparesis (ascending pattern) and facial diplegia         Motor neuropathy with CB                   NA                            5
  39    Second   URI               Quadriparesis (descending pattern) and bulbar symptoms                                 Motor neuropathy with CB                   IgG anti-GD1a                                                                                                                          
  2     M        58                First                                                                                  None                                       Cerebellar ataxia, ptosis, and paresthesia                    Sensory neuropathy, unclassified           NA                            3
  65    Second   URI               Cerebellar ataxia, ptosis, and paresthesia                                             Sensory neuropathy, unclassified           IgG anti-GD1b and anti-GQ1b                                                                                                            
  68    Third    Arthralgia        Cerebellar ataxia, ptosis, and paresthesia                                             Sensory neuropathy, unclassified           IgG anti-GD1b and anti-GQ1b                                                                                                            
  3     M        29                First                                                                                  None                                       Quadriparesis                                                 Motor neuropathy with CB, demyelinating    NA                            3
  40    Second   Gastroenteritis   Quadriparesis                                                                          Motor neuropathy with CB, demyelinating    IgG anti-GD1b and anti-GM1                                                                                                             
  4     F        56                First                                                                                  None                                       Distal leg weakness and sensory loss                          SM polyneuropathy with CB, demyelinating   NA                            3
  68    Second   URI               Distal leg weakness and sensory loss                                                   SM polyneuropathy with CB, demyelinating   NA                                                                                                                                     
  69    Third    Gastroenteritis   Distal leg weakness and sensory loss                                                   SM polyneuropathy, demyelinating           IgM anti-GM1                                                                                                                           
  5     M        25                First                                                                                  URI                                        Bulbar symptoms, ophthalmoplegia, ataxia, and quadriparesis   SM polyneuropathy, unclassified            IgG GA1 and GSC-Abs           4
  28    Second   URI               Bulbar symptoms, ophthalmoplegia, ataxia, and weakness of the lower extremities        SM polyneuropathy, unclassified            GSC-Abs                                                                                                                                
  33    Third    URI               Bulbar symptoms, ophthalmoplegia, quadriparesis, tremor, and disturbed consciousness   SM polyneuropathy, demyelinating           GSC-Abs                                                                                                                                
  6     M        63                First                                                                                  None                                       Bulbar symptoms, ophthalmoplegia, and ataxia                  Unremarkable                               IgG anti-GT1a and anti-GQ1b   Our case
  64    Second   URI               Bulbar symptom, ophthalmoplegia, ataxia, and quadriparesis                             SM polyneuropathy with CB, demyelinating   IgG anti-GT1a and anti-GQ1b                                                                                                            

CB: conduction block, F: female, GSC-Abs: anti-ganglioside complex antibodies, M: male, NA: not applicable, NCS: nerve conduction study, SM: sensorimotor, URI: upper respiratory tract infection.
